LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,416,108
تعداد دریافت فایل اصل مقاله11,291,824
Danesh, Hiva, Anbiaei, Robab, Ziamajidi, Nasrin, Farhadian, Maryam, Barartabar, Zeinab, Abbasalipourkabir, Roghayeh. (1402). Association between Metabolic Syndrome Risk Factors and Immunohistochemical Profile in Women with Breast Cancer. سامانه مدیریت نشریات علمی, 48(5), 456-464. doi: 10.30476/ijms.2022.95039.2673
Hiva Danesh; Robab Anbiaei; Nasrin Ziamajidi; Maryam Farhadian; Zeinab Barartabar; Roghayeh Abbasalipourkabir. "Association between Metabolic Syndrome Risk Factors and Immunohistochemical Profile in Women with Breast Cancer". سامانه مدیریت نشریات علمی, 48, 5, 1402, 456-464. doi: 10.30476/ijms.2022.95039.2673
Danesh, Hiva, Anbiaei, Robab, Ziamajidi, Nasrin, Farhadian, Maryam, Barartabar, Zeinab, Abbasalipourkabir, Roghayeh. (1402). 'Association between Metabolic Syndrome Risk Factors and Immunohistochemical Profile in Women with Breast Cancer', سامانه مدیریت نشریات علمی, 48(5), pp. 456-464. doi: 10.30476/ijms.2022.95039.2673
Danesh, Hiva, Anbiaei, Robab, Ziamajidi, Nasrin, Farhadian, Maryam, Barartabar, Zeinab, Abbasalipourkabir, Roghayeh. Association between Metabolic Syndrome Risk Factors and Immunohistochemical Profile in Women with Breast Cancer. سامانه مدیریت نشریات علمی, 1402; 48(5): 456-464. doi: 10.30476/ijms.2022.95039.2673

Association between Metabolic Syndrome Risk Factors and Immunohistochemical Profile in Women with Breast Cancer

Iranian Journal of Medical Sciences
مقاله 3، دوره 48، شماره 5، آذر 2023، صفحه 456-464    اصل مقاله (296.2 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2022.95039.2673
نویسندگان
Hiva Danesh1؛ Robab Anbiaei2؛ Nasrin Ziamajidi1؛ Maryam Farhadian3؛ Zeinab Barartabar1؛ Roghayeh Abbasalipourkabir* 1
1Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2Department of Radiotherapy, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Biostatistics, School of Public Health, Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran
چکیده
Background: The association between metabolic syndrome (MetS) and breast cancer may significantly impact the mortality and incidence of breast cancer. This study aimed to assess the association between MetS risk factors and immunohistochemical (IHC) profiles in women with breast cancer.
Methods: This cross-sectional study used the medical records of 300 breast cancer patients with an average age of 53.11±12.97 years in the Chemotherapy and Radiation Therapy Clinic of Dr. Anbiai, Tehran, Iran (2020-2021). The cases were divided into five subgroups including luminal A, luminal B (HER-2-), luminal B (HER-2+), HER-2 overexpressing, and triple negative.
Results: There was no difference in the prognostic indicators between the presence and absence of MetS in women with breast cancer. A higher proportion of luminal A tumors (39.3%), luminal B (HER-2+) (25%), triple-negative (17%), luminal B (HER-2-) (10.7%), HER-2 overexpression (8%) was observed in women with MetS than those without MetS. Multivariate logistic regression analysis showed that patients with MetS had a 41% higher chance of developing luminal A than those without MetS, and patients with a BMI≥30 Kg/m2 had an 80% higher chance of developing luminal B (HER-2+) than those with a BMI<30 Kg/m2. Moreover, women with a waist circumference higher than 88 cm had a 14 % lower chance of developing Luminal B (HER-2+) 
than those with a waist circumference less than 88 cm.
Conclusion: There was no difference in prognostic indicators and IHC profile in patients with and without MetS.

تازه های تحقیق

Hiva Danesh (Google Scholar)

Roghayeh Abbasalipourkabir (Google Scholar)

کلیدواژه‌ها
Breast neoplasms؛ Immunohistochemistry؛ Metabolic syndrome
سایر فایل های مرتبط با مقاله
مراجع
  1. Brisken C. Hormonal control of alveolar development and its implications for breast carcinogenesis. J Mammary Gland Biol Neoplasia. 2002;7:39-48. doi: 10.1023/a:1015718406329. PubMed PMID: 12160085.
  2. Allred DC. Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr. 2010;2010:134-8. doi: 10.1093/jncimonographs/lgq035. PubMed PMID: 20956817; PubMed Central PMCID: PMCPMC5161057.
  3. Jafari A, Goudarzian AH, Bagheri Nesami M. Depression in Women with Breast Cancer: A Systematic Review of Cross-Sectional Studies in Iran. Asian Pac J Cancer Prev. 2018;19:1-7. doi: 10.22034/APJCP.2018.19.1.1. PubMed PMID: 29373872; PubMed Central PMCID: PMCPMC5844601.
  4. Molah Karim SA, Ali Ghalib HH, Mohammed SA, Fattah FHR. The incidence, age at diagnosis of breast cancer in the Iraqi Kurdish population and comparison to some other countries of Middle-East and West. Int J Surg. 2015;13:71-5. doi: 10.1016/j.ijsu.2014.11.029. PubMed PMID: 25433249.
  5. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380:1840-50. doi: 10.1016/S0140-6736(12)60919-2. PubMed PMID: 23079588.
  6. Kabat GC, Kim M, Chlebowski RT, Khandekar J, Ko MG, McTiernan A, et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:2046-53. doi: 10.1158/1055-9965.EPI-09-0235. PubMed PMID: 19567502; PubMed Central PMCID: PMCPMC6204126.
  7. Agnoli C, Berrino F, Abagnato CA, Muti P, Panico S, Crosignani P, et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis. 2010;20:41-8. doi: 10.1016/j.numecd.2009.02.006. PubMed PMID: 19361966; PubMed Central PMCID: PMCPMC2819536.
  8. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469-80. doi: 10.1111/j.1464-5491.2006.01858.x. PubMed PMID: 16681555.
  9. Wani B, Aziz SA, Ganaie MA, Mir MH. Metabolic Syndrome and Breast Cancer Risk. Indian J Med Paediatr Oncol. 2017;38:434-9. doi: 10.4103/ijmpo.ijmpo_168_16. PubMed PMID: 29333008; PubMed Central PMCID: PMCPMC5759060.
  10. Cazzaniga M, Bonanni B. Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? Anticancer Res. 2018;38:4393-402. doi: 10.21873/anticanres.12741. PubMed PMID: 30061203.
  11. Mayengbam SS, Singh A, Pillai AD, Bhat MK. Influence of cholesterol on cancer progression and therapy. Transl Oncol. 2021;14:101043. doi: 10.1016/j.tranon.2021.101043. PubMed PMID: 33751965; PubMed Central PMCID: PMCPMC8010885.
  12. Motoki AH, Buttros DAB, Gaspar AL, Almeida-Filho BS, Carvalho-Pessoa E, Vespoli HDL, et al. Association Between Metabolic Syndrome and Immunohistochemical Profile at Breast Cancer Diagnosis in Postmenopausal Women. Clin Breast Cancer. 2022;22:e253-e61. doi: 10.1016/j.clbc.2021.07.009. PubMed PMID: 34465534.
  13. Khare S, Irrinki S, Sakaray YR, Bal A, Singh T, Singh G. Metabolic Syndrome in Breast Cancer Patients: An Observational Study. Breast Cancer (Auckl). 2021;15:11782234211026788. doi: 10.1177/11782234211026788. PubMed PMID: 34629874; PubMed Central PMCID: PMCPMC8493313.
  14. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9:490-9. doi: 10.1007/s13311-012-0135-8. PubMed PMID: 22976615; PubMed Central PMCID: PMCPMC3441936.
  15. Can A, Alacacioglu A, Kucukzeybek Y, Erten C, Cokmert S, Demir L, et al. The relationship of insulin resistance and metabolic syndrome with known breast cancer prognostic factors in postmenopausal breast cancer patients. J BUON. 2013;18:845-50. PubMed PMID: 24344007.
  16. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-47. doi: 10.1093/annonc/mdr304. PubMed PMID: 21709140; PubMed Central PMCID: PMCPMC3144634.
  17. Berrino F, Villarini A, Traina A, Bonanni B, Panico S, Mano MP, et al. Metabolic syndrome and breast cancer prognosis. Breast Cancer Res Treat. 2014;147:159-65. doi: 10.1007/s10549-014-3076-6. PubMed PMID: 25104441.
  18. Deen D. Metabolic syndrome: time for action. Am Fam Physician. 2004;69:2875-82. PubMed PMID: 15222652.
  19. Song SH, Hardisty CA. Diagnosing metabolic syndrome in type 2 diabetes: does it matter? QJM. 2008;101:487-91. doi: 10.1093/qjmed/hcn034. PubMed PMID: 18353792.
  20. Wu YT, Luo QQ, Li X, Arshad B, Xu Z, Ran L, et al. Clinical study on the prevalence and comparative analysis of metabolic syndrome and its components among Chinese breast cancer women and control population. J Cancer. 2018;9:548-55. doi: 10.7150/jca.22968. PubMed PMID: 29483960; PubMed Central PMCID: PMCPMC5820922.
  21. Saadatian V, Ghareh S, Shakeri M, Emadzadeh M, Taraz Jamshidi S, Emadzadeh A. Frequency of Metabolic Syndrome among Female Patients Admitted in Psychiatry Ward. Medical Journal of Mashhad University of Medical Sciences. 2011;54:230-7.
  22. Amiri A, Hakimi A. The study of prevalence of metabolic syndrome among nurses of Shahid Mohammadi Hospital of Bandar Abbas city, Iran. Journal of Clinical Nursing and Midwifery. 2017;6:1-8.
  23. Dubnov G, Brzezinski A, Berry EM. Weight control and the management of obesity after menopause: the role of physical activity. Maturitas. 2003;44:89-101. doi: 10.1016/s0378-5122(02)00328-6. PubMed PMID: 12590004.
  24. Al-Lawati JA, Mohammed AJ, Al-Hinai HQ, Jousilahti P. Prevalence of the metabolic syndrome among Omani adults. Diabetes Care. 2003;26:1781-5. doi: 10.2337/diacare.26.6.1781. PubMed PMID: 12766109.
  25. Deurenberg-Yap M, Chew SK, Lin VF, Tan BY, van Staveren WA, Deurenberg P. Relationships between indices of obesity and its co-morbidities in multi-ethnic Singapore. Int J Obes Relat Metab Disord. 2001;25:1554-62. doi: 10.1038/sj.ijo.0801739. PubMed PMID: 11673781.
  26. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009;169:572-8. doi: 10.1001/archinternmed.2008.599. PubMed PMID: 19307519.
  27. Fernandes J, Lofgren IE. Prevalence of metabolic syndrome and individual criteria in college students. J Am Coll Health. 2011;59:313-21. doi: 10.1080/07448481.2010.508084. PubMed PMID: 21308592.
  28. Gonzalez Deschamps E, Palmeros Exsome C, Villanueva Sanchez J, Torres Flores B, Bastida S, Vaquero MP, et al. Metabolic syndrome prevalence and its association with the body mass index in university students. Med Clin (Barc). 2007;129:766-9. doi: 10.1157/13113766. PubMed PMID: 18093476.
  29. Khalid ME. The prevalence of abdominal obesity and its associated risk factors in married, non-pregnant women born and living in high altitude, southwestern, Saudi Arabia. Saudi Med J. 2007;28:1875-80. PubMed PMID: 18060220.
  30. Dalleck LC, Kjelland EM. The prevalence of metabolic syndrome and metabolic syndrome risk factors in college-aged students. Am J Health Promot. 2012;27:37-42. doi: 10.4278/ajhp.100415-QUAN-116. PubMed PMID: 22950924.
  31. Morrell JS, Lofgren IE, Burke JD, Reilly RA. Metabolic syndrome, obesity, and related risk factors among college men and women. J Am Coll Health. 2012;60:82-9. doi: 10.1080/07448481.2011.582208. PubMed PMID: 22171733.
  32. Palaniappan L, Carnethon MR, Wang Y, Hanley AJ, Fortmann SP, Haffner SM, et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27:788-93. doi: 10.2337/diacare.27.3.788. PubMed PMID: 14988303.
  33. Cheung BM, Wat NM, Tam S, Thomas GN, Leung GM, Cheng CH, et al. Components of the metabolic syndrome predictive of its development: a 6-year longitudinal study in Hong Kong Chinese. Clin Endocrinol (Oxf). 2008;68:730-7. doi: 10.1111/j.1365-2265.2007.03110.x. PubMed PMID: 17980012.
  34. Healy LA, Ryan AM, Carroll P, Ennis D, Crowley V, Boyle T, et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol). 2010;22:281-8. doi: 10.1016/j.clon.2010.02.001. PubMed PMID: 20189371.
  35. Capasso I, Esposito E, Pentimalli F, Crispo A, Montella M, Grimaldi M, et al. Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther. 2010;10:1240-3. doi: 10.4161/cbt.10.12.13473. PubMed PMID: 20935521.
  36. Grybach SM, Polishchuk LZ, Chekhun VF. Analysis of the survival of patients with breast cancer depending on age, molecular subtype of tumor and metabolic syndrome. Exp Oncol. 2018;40:243-8. PubMed PMID: 30285006.
آمار
تعداد مشاهده مقاله: 859
تعداد دریافت فایل اصل مقاله: 592


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب